Skip to main content
Livermore
Livermore
ZHEN

Morgan Stanley

SEC CIK
0000895421
Latest filing
Aug 13, 2026

APLS holding history

Apellis Pharmaceuticals, Inc. in every 13F filed by Morgan Stanley, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

APLS overviewAll 13F holders of APLSFull Q2 2026 holdings

Shares (Q2 2026)
0
Sold out in Q2 2026
Value
$0
% of portfolio
0.0%
Quarters held
21
Since Q1 2021
Holdings of APLS by Morgan Stanley, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20260$00.0%−10,042,399−100.0%Sold outHolders
Q1 202610,042,399$404.0M<0.1%+869,395+9.5%AddedHolders
Q4 20259,173,004$230.4M<0.1%−470,244−4.9%ReducedHolders
Q3 20259,643,248$218.2M<0.1%−108,953−1.1%ReducedHolders
Q2 20259,752,201$168.8M<0.1%+126,078+1.3%AddedHolders
Q1 20259,626,123$210.5M<0.1%−1,1040.0%ReducedHolders
Q4 20249,627,227$307.2M<0.1%+6,237,442+184.0%AddedHolders
Q3 20243,389,785$97.8M<0.1%+1,270,888+60.0%AddedHolders
Q2 20242,118,897$81.3M<0.1%+481,279+29.4%AddedHolders
Q1 20241,637,618$96.3M<0.1%−1,459,523−47.1%ReducedHolders
Q4 20233,097,141$185.4M<0.1%+1,488,145+92.5%AddedHolders
Q3 20231,608,996$61.2M<0.1%+852,331+112.6%AddedHolders
Q2 2023756,665$68.9M<0.1%+3,803+0.5%AddedHolders
Q1 2023752,862$49.7M<0.1%+452,979+151.1%AddedHolders
Q4 2022299,883$15.5M<0.1%+76,607+34.3%AddedHolders
Q3 2022223,276$15.3M<0.1%−229,744−50.7%ReducedHolders
Q2 2022453,020$20.5M<0.1%+199,631+78.8%AddedHolders
Q1 2022253,389$12.9M<0.1%+185,730+274.5%AddedHolders
Q4 202167,659$3.20M<0.1%−109,637−61.8%ReducedHolders
Q3 2021177,296$5.84M<0.1%−52,045−22.7%ReducedHolders
Q2 2021229,341$14.5M<0.1%+77,317+50.9%AddedHolders
Q1 2021152,024$6.52M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.